Clinical Trials Logo

Clinical Trial Summary

The investigators are registering all nephrotic syndrome (NS) patients regardless of the primary causes and developing a NS database in China. Patients will be followed-up and both baseline and follow-up information will be recorded in the registration system. The treatment response, longitudinal changes of renal function, renal survival, patient survival, infection events and acute kidney injury etc, will be analyzed using the NS database.


Clinical Trial Description

The investigators are registering all NS patients regardless of the primary causes in China. Patients' demographic characteristics (including age, gender, height, weight, BMI, smoking, drinking, and education), clinical characteristics (including systolic blood pressure, diastolic blood pressure, primary cause of NS, and lab measurements of serum, urine), pathological characteristics, treatment and treatment response, complications and outcomes. Patients will be followed up, the demographic, clinical characteristics, treatment, lab tests of blood and urine and complications of patients will be collected and recorded at each visit. The investigators also record the outcome at each visit, such as treatment response, longitudinal changes of renal function, hospitalization, occurrence of infection or cardiovascular events etc. The outcomes will be analyzed using the NS database. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03001934
Study type Observational [Patient Registry]
Source Sun Yat-sen University
Contact Xueqing Yu, M.D. & Ph.D
Email [email protected]
Status Recruiting
Phase
Start date April 2016
Completion date December 2028

See also
  Status Clinical Trial Phase
Completed NCT02238418 - Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria. Phase 4
Completed NCT01895894 - Mycophenolate Mofetil in Pediatric Steroid Dependent Nephrotic Syndrome Phase 4
Completed NCT01411982 - Role of PACAP in Nehprotic Syndrome N/A
Recruiting NCT00308321 - Long Term Tapering or Standard Steroids for Nephrotic Syndrome Phase 4
Active, not recruiting NCT03326037 - Study of The Association of Mutations in The NPHS2 Gene and Nephrotic Syndrome in Children and Adults in Middle East
Recruiting NCT01240564 - The Nephrotic Syndrome Study Network (NEPTUNE) N/A
Completed NCT01252901 - Registry for Patients With Wilms' Tumor Suppressor Gene 1 (WT1) Mutation Associated Diseases N/A
Completed NCT01197040 - Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic Syndrome Phase 3
Terminated NCT00883636 - Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis N/A
Completed NCT00035334 - Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis Phase 2/Phase 3
Terminated NCT00004466 - Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia Secondary to Nephrotic Syndrome Phase 2
Terminated NCT04558892 - Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome. Phase 2/Phase 3
Completed NCT02257697 - A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome Phase 3
Completed NCT00362531 - Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome Phase 2/Phase 3
Completed NCT00289328 - Glucocorticoid-induced Osteopenia in Children N/A
Completed NCT00001212 - Drug Therapy in Lupus Nephropathy Phase 2
Active, not recruiting NCT03332420 - The Efficacy of Huaiqihuang Granule in Children With Primary Nephrotic Syndrome
Completed NCT02438982 - Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome Phase 3
Completed NCT02132195 - Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome Phase 3
Completed NCT01845428 - Lipid Lowering Agents to Limit Lipid Oxidation and Activation of Clotting System in Nephrotic Syndrome Phase 1